- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03508739
Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition
March 3, 2023 updated by: Jessica R.Wilson, MD, MS, University of Pennsylvania
Glucagon-like Peptide-1 Metabolism in the Setting of Acute Neprilysin Inhibition
Type 2 diabetes is common, increases in prevalence with age, and patients with diabetes have an increased risk of cardiovascular disease.
A relatively new cardiovascular medication currently used for the treatment of heart failure in the United States inhibits an enzyme that breaks down a variety of signaling hormones.
This clinical trial tests if it may also be a target for the treatment of diabetes by decreasing the breakdown of a hormone that increases insulin release after a meal.
Study Overview
Status
Suspended
Intervention / Treatment
Detailed Description
This study will test the hypothesis that neprilysin inhibition with sacubitril/valsartan will increase endogenous glucagon-like peptide-1 (GLP-1) after a mixed meal compared to valsartan.
The primary statistical analysis will be within subject comparison (paired t-test or nonparametric equivalent) of area under the curve intact GLP-1 after the meal during sacubitril/valsartan compared to valsartan.
Neprilysin inhibition may be a new drug target for the treatment of type 2 diabetes by increasing intact GLP-1 and may be of particular benefit to individuals with increased risk of hypoglycemia and cardiovascular disease.
Study Type
Interventional
Enrollment (Anticipated)
25
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women ages 18-80 years
Type 2 diabetes mellitus (T2DM) or pre-diabetes, controlled by diet alone or metformin therapy and elevated blood pressure
- Pre-diabetes is defined as fasting plasma glucose of 100-125 mg/dL, plasma glucose of 140-199 mg/dL two hours after 75g oral glucose load, or hemoglobin A1C 5.7-6.4%. T2DM is defined as fasting plasma glucose of ≥126 mg/dL, plasma glucose of ≥200 mg/dL two hours after 75g oral glucose load, or hemoglobin A1C ≥6.5%.
- Elevated blood pressure is defined as systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥80 mmHg on three occasions or therapy with antihypertensive medication(s) for a minimum of three months.
For female subjects, the following conditions must be met:
- Postmenopausal status for at least one year or
- Status post-surgical sterilization, or
- If childbearing potential, utilization of birth control (barrier methods, abstinence, hormonal contraception, etc) and willingness to undergo regular beta hCG monitoring prior to drug treatment and on each study day. (Valsartan is pregnancy category D.)
Exclusion Criteria:
- Type 1 diabetes
- Poorly controlled T2DM, defined as hemoglobin A1C ≥8.7%
- Use of anti-diabetic medications other than metformin for over 24 months prior to initiation of the study.
- Requiring the need for insulin therapy
- Secondary hypertension
- Severe hypertension requiring the use of more than two anti-hypertensive agents other than a stable dose of diuretic or blood pressure > 180/110 mmHg
- Subjects who have participated in a weight-reduction program during the last 6 months and whose weight has increased or decreased more than 5 kg over the preceding 6 months
- Pregnancy or breastfeeding
- History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, angiotensin converting enzyme inhibitors, ARBs, or NEP inhibitors, as well as known or suspected contraindications to the study drugs
- History of angioedema
- History of pancreatitis or known pancreatic lesions
- Clinically significant gastrointestinal impairment that could interfere with drug absorption
- Significant cardiovascular disease such as myocardial infarction or cardiovascular surgery or angioplasty within six months prior to enrollment, presence of angina pectoris, arrhythmia with history of or risk of syncopal episodes or need for antiarrhythmic therapy, congestive heart failure (LV hypertrophy and diastolic dysfunction acceptable), deep vein thrombosis, pulmonary embolism, second- or third-degree AV block, mitral valve stenosis, hypertrophic cardiomyopathy, or coronary or carotid artery disease likely to require surgical or percutaneous intervention within six months of screening
- Impaired hepatic function (aspartate amino transaminase [AST] and/or alanine amino transaminase [ALT] >3 x upper limit of normal range)
- Impaired renal function (eGFR< 50mL/min/1.73m2 as determined by the MDRD equation)
- History or presence of immunological or hematological disorders
- Serum potassium >5.2 mmol/L at screening
- History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or transient ischemic attack within six months
- Hematocrit <35%
- Diagnosis of asthma requiring use of inhaled beta agonist more than once a week
- Clinically significant gastrointestinal impairment that could interfere with drug absorption
- Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult, such as arthritis treated with daily use of non-steroidal anti-inflammatory drugs
- Treatment with chronic systemic glucocorticoid therapy within the last year
- Treatment with systemic glucocorticoid therapy acutely within six weeks prior to enrollment
- Treatment with lithium salts
- History of alcohol or drug abuse
- Treatment with anticoagulation
- Treatment with any investigational drug in the one month preceding the study
- Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study
- Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARM 1: randomization order AB
Subjects will present for a baseline mixed meal study day 1 (no medication).
Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order AB).
At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3.
After an IV is placed, neprilysin activity will be measured at baseline.
Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides.
Following this, subjects will ingest a mixed meal.
Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total.
Blood pressure and heart rate will be monitored.
|
study day 2 for AB and study day 3 for BA
Other Names:
study day 3 for AB and study day 2 for BA
Other Names:
|
Experimental: ARM 2: randomization order BA
Subjects will present for a baseline mixed meal study day 1 (no medication).
Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order BA).
At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3.
After an IV is placed, neprilysin activity will be measured at baseline.
Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides.
Following this, subjects will ingest a mixed meal.
Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total.
Blood pressure and heart rate will be monitored.
|
study day 2 for AB and study day 3 for BA
Other Names:
study day 3 for AB and study day 2 for BA
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intact glucagon like peptide-1 (GLP-1) levels after the mixed meal
Time Frame: This will be measured just before the meal and after the meal at pre-specified time points for a total of four hours. (Time points 0 to 4 hours)
|
GLP-1 is a hormone released after a meal that has been shown to improve insulin and glucose dynamics.
It is a target for diabetes therapies.
We will compare GLP-1 levels during the different drug treatments and at baseline.
|
This will be measured just before the meal and after the meal at pre-specified time points for a total of four hours. (Time points 0 to 4 hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin levels after the mixed meal
Time Frame: This will be measured just before the meal and after the meal at pre-specified time points for a total of four hours. (Time points 0 to 4 hours)
|
Insulin is a hormone released from the pancreas that helps with blood glucose control.
We will measure insulin levels during the different drug treatments and at baseline.
|
This will be measured just before the meal and after the meal at pre-specified time points for a total of four hours. (Time points 0 to 4 hours)
|
Blood glucose levels after the mixed meal
Time Frame: This will be measured just before the meal and after the meal at pre-specified time points for a total of four hours. (Time points 0 to 4 hours)
|
We will compare blood glucose levels during the different drug treatments and at baseline.
|
This will be measured just before the meal and after the meal at pre-specified time points for a total of four hours. (Time points 0 to 4 hours)
|
Triglyceride levels after the mixed meal
Time Frame: This will be measured just before the meal and after the meal at pre-specified time points for a total of four hours. (Time points 0 to 4 hours)
|
Triglycerides are a component of a routine lipid/ cholesterol panel.
They rise in the setting of increased fat intake.
GLP-1 is thought to decrease triglyceride levels.
We will compare triglyceride levels during the different drug treatments and at baseline.
|
This will be measured just before the meal and after the meal at pre-specified time points for a total of four hours. (Time points 0 to 4 hours)
|
Neprilysin enzyme (drug) activity at baseline, during sacubitril/valsartan, and during valsartan
Time Frame: Time points -120 min (before drug given) and 0 min (2 hours after drug dose, just prior to the meal)
|
Neprilysin is an enzyme that breaks down several proteins, including glucagon-like peptide-1 (GLP-1).
Sacubitril in sacubitril/valsartan is a pro-drug of a neprilysin inhibitor.
This assay level will help to determine if the changes seen after the meal are related to alterations in this enzyme activity and administration of the drug sacubitril/valsartan compared to valsartan.
We will measure this before the medication is administered (thus at baseline) and two hours after the drug is administered and just prior to the mixed meal.
|
Time points -120 min (before drug given) and 0 min (2 hours after drug dose, just prior to the meal)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jessica R Wilson, MD, MSCI, University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2018
Primary Completion (Anticipated)
June 1, 2024
Study Completion (Anticipated)
June 30, 2024
Study Registration Dates
First Submitted
November 7, 2017
First Submitted That Met QC Criteria
April 23, 2018
First Posted (Actual)
April 26, 2018
Study Record Updates
Last Update Posted (Estimate)
March 6, 2023
Last Update Submitted That Met QC Criteria
March 3, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Hypertension
- Diabetes Mellitus, Type 2
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Valsartan
- Sacubitril and valsartan sodium hydrate drug combination
Other Study ID Numbers
- 828731
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
This study will not have large scale genomic data to share.
The maximum number of participants will be 50.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
Clinical Trials on Sacubitril/Valsartan 200mg (blinded)
-
Qingdao Central HospitalNot yet recruitingMyocardial Infarction | HypertensionChina
-
Viatris Inc.Not yet recruiting
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompleted
-
Damanhour UniversityTanta UniversityCompleted
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular Diseases | Hypertension | Obesity | Nocturnal Blood Pressure | Natriuretic Peptides | Renin-Angiotensin-Aldosterone SystemUnited States
-
Bio-innova Co., LtdNot yet recruiting
-
Novartis PharmaceuticalsCompletedHeart Failure With Preserved Ejection Fraction (HFpEF)United States, Canada
-
Viatris Inc.Not yet recruitingBioequivalence StudyThailand
-
University Hospital, ToulouseTerminated